Hypopituitarism: when the master gland falls short — the AU GP guide

What is hypopituitarism?

The pituitary gland sits at the base of the brain in a bony hollow called the sella turcica. About the size of a pea, it coordinates most of the body’s hormonal systems — earning the title “master gland.” When the pituitary fails to produce one or more of its hormones, the condition is called hypopituitarism. When all hormones are affected, it is called panhypopituitarism.

Therapeutic Guidelines (eTG) and the Endocrine Society of Australia identify six functional axes through the pituitary: cortisol (via ACTH), thyroid hormone (via TSH), sex hormones — oestrogen and testosterone — (via LH and FSH), growth hormone (via GH), prolactin, and water balance (via ADH, the anti-diuretic hormone, stored in the posterior pituitary).

Deficiency can affect just one axis or all of them. The most dangerous — and the one always diagnosed and replaced first — is cortisol deficiency, because without it the body cannot mount a stress response.

Australian prevalence estimates suggest roughly 45 per 100,000 people have some degree of hypopituitarism, with an incidence of approximately 4 per 100,000 per year.

A. Core clinical — the AU general practice framework

Causes

Higham, Johannsson and Shalet (Lancet 2016) summarise the leading causes:

Pituitary adenoma and its treatment — benign pituitary tumours are the most common cause in adults; surgery and radiotherapy each carry a risk of damaging surrounding normal pituitary tissue.

Traumatic brain injury (TBI) — approximately 12% of patients with moderate-to-severe TBI develop persistent pituitary deficiency at 12 months. (Schneider et al., JAMA 2007) Subarachnoid haemorrhage carries a similar risk of about 20%.

Sheehan syndrome — pituitary infarction following massive postpartum haemorrhage with hypotension. The classic delayed presentation includes failure of breastmilk, persistent amenorrhoea, and fatigue — often diagnosed years after a complicated delivery.

Lymphocytic hypophysitis — autoimmune inflammation of the gland, occurring peripartum or in people receiving immune-checkpoint-inhibitor (ICI) cancer treatments. Ipilimumab causes hypophysitis in 10–17% of recipients; nivolumab and pembrolizumab less commonly.

Pituitary apoplexy — haemorrhage or infarction of a (often previously unknown) pituitary adenoma. Presents as sudden severe retro-orbital or thunderclap headache, double vision, visual loss, altered consciousness, and low blood pressure. This is a neurosurgical emergency.

Infiltrative disease — sarcoidosis, haemochromatosis, Langerhans cell histiocytosis, IgG4-related disease, tuberculosis.

Craniopharyngioma — a cystic benign tumour at the pituitary stalk or hypothalamus, with a bimodal age distribution (childhood and older adulthood).

Recognising hypopituitarism: symptoms by axis

Because each hormonal axis controls different functions, hypopituitarism can mimic many other conditions — and is frequently diagnosed late. Key symptom patterns:

Cortisol deficiency — profound fatigue, postural dizziness, nausea, anorexia, weight loss, low blood pressure, and low sodium (hyponatraemia). Critically, unlike primary adrenal insufficiency (Addison’s disease), there is no skin darkening (hyperpigmentation) in hypopituitarism, because ACTH is low rather than elevated. Hyperkalaemia is also absent because aldosterone (controlled by the adrenal gland itself, not the pituitary) is preserved.

Thyroid hormone deficiency — cold intolerance, weight gain, constipation, dry skin, bradycardia, depression, hair thinning. A clinically important diagnostic trap: in central hypothyroidism the TSH level can appear normal or low — it is the free T4 (fT4) level that confirms the diagnosis, not the TSH alone.

Sex hormone deficiency — women: missed or irregular periods, hot flushes, vaginal dryness, reduced libido, infertility. Men: low libido, erectile dysfunction, reduced frequency of shaving, loss of axillary and pubic hair, reduced muscle bulk, infertility.

Growth hormone deficiency in adults — reduced exercise capacity, increased central adiposity, impaired quality of life, dyslipidaemia, reduced bone density. Symptoms are non-specific and often attributed to other causes.

ADH deficiency (central diabetes insipidus) — passing large volumes of urine (often over 3 litres per day), extreme thirst, preference for very cold fluids, nocturia. Serum sodium can rise if fluid intake does not keep pace with losses.

Investigations

eTG and the Fleseriu Endocrine Society 2016 guideline recommend the following baseline tests when hypopituitarism is suspected:

• 9 am cortisol and ACTH (paired) — cortisol below 100 nmol/L strongly supports adrenal insufficiency; above 500 nmol/L generally excludes it. ACTH is low or inappropriately normal in secondary (pituitary-origin) adrenal insufficiency.
• Free T4 and TSH — fT4 is the key test; TSH is unreliable as a standalone marker in central hypothyroidism.
• LH, FSH, and testosterone (men, 8–11 am) or oestradiol with LH and FSH (pre-menopausal women on cycle day 2–5).
• IGF-1 — surrogate marker for growth hormone secretion, interpreted against age- and sex-matched references.
• Prolactin — low in Sheehan syndrome; mildly elevated from stalk compression in other masses.
• Serum osmolality paired with urine osmolality if polyuria is present, as a diabetes insipidus screen.
• FBC, UEC, LFTs, blood glucose — normochromic normocytic anaemia and hyponatraemia are common.
• MRI pituitary with gadolinium — essential imaging for structural cause. MBS item 63551/63556.

Dynamic tests — short Synacthen test, insulin tolerance test, glucagon stimulation — are arranged by the endocrinologist to confirm cortisol and growth hormone reserve.

B. Hormone replacement — the sequence that saves lives

The replacement priority order reflects a biological imperative, not merely a guideline preference. Starting thyroid hormone before adequate cortisol replacement can precipitate an adrenal crisis by accelerating cortisol clearance before the body can compensate.

Per eTG and the Australian Medicines Handbook (AMH):

Step 1 — Glucocorticoid replacement first. Hydrocortisone 15–25 mg per day in 2–3 divided doses — typically 10 mg on waking, 5 mg at lunch, and 5 mg mid-afternoon. No evening dose is given (it disrupts sleep and raises nocturnal cortisol). Prednisolone 3–5 mg each morning is an alternative for once-daily dosing. Serum cortisol levels cannot be used to monitor adequacy of replacement — titration is clinical.

Step 2 — Levothyroxine, after at least one week on glucocorticoid. Dose titrated to target fT4 in the mid-to-upper normal range. TSH is not used to guide levothyroxine dosing in central hypothyroidism — it remains unreliable.

Step 3 — Sex steroids. Men: testosterone preparations (gel, injection) under PBS Authority Required for confirmed androgen deficiency (total testosterone below 8 nmol/L on two morning samples with clinical features). Women: oestradiol — transdermal preparations preferred — with cyclical progesterone if the uterus is present.

Step 4 — Growth hormone. Adult growth hormone deficiency requires two confirmatory stimulation tests (or one test with a convincing clinical context per AACE criteria). Somatropin is available under the PBS Section 100 Highly Specialised Drugs programme, specialist-initiated. Cost and access are barriers for some patients.

Step 5 — Desmopressin (for central diabetes insipidus). Intranasal, oral, or sublingual formulations, titrated to symptom control and serum sodium. Annual sodium monitoring is essential to detect iatrogenic hyponatraemia from over-replacement.

C. Stress-dose rules — a life-saving conversation

Without stress-dose education, a routine viral illness or dental procedure can become a preventable emergency for anyone on cortisol replacement. Per Hahner et al. (Eur J Endocrinol 2015) and Addisons Australia:

• Minor illness (mild cold, low-grade fever): double the usual daily hydrocortisone dose for 2–3 days.
• Moderate illness (fever ≥38°C, a single episode of vomiting, minor procedure under general anaesthesia, dental surgery): triple the usual oral dose for the duration and 24 hours after.
• Severe illness (vomiting or diarrhoea preventing oral tablets, sepsis, major trauma, major surgery, labour): inject hydrocortisone 100 mg intramuscularly immediately and attend an emergency department. In hospital, IV hydrocortisone 100 mg every six hours until stable, then taper.
• Minor surgery (local anaesthetic only): double the oral dose on the day; specific dental extractions under local anaesthesia generally need only doubling, not IV cover.

Every person on cortisol replacement should be provided with and educated about:

• A written sick-day plan from their endocrinologist.
• A steroid emergency card to carry in their wallet.
• A MedicAlert bracelet or pendant — critical in emergencies where the person cannot speak for themselves.
• An emergency injection kit (hydrocortisone sodium succinate 100 mg vial, syringe, administration instructions) — with a family member or carer trained to use it.

Pituitary Foundation Australia and Addisons Australia provide plain-language resources on these protocols.

D. Australian operations

MBS items for GP-led care:

• Standard GP consultations: items 23, 36, 44.
• GPCCMP preparation and review for complex multi-axis hypopituitarism: item 965 / 967.
• Mental Health Care Plan when quality of life is significantly affected: items 2715 / 2717.
• MRI pituitary with contrast: items 63551 / 63556.
• DEXA for bone density monitoring (chronic glucocorticoid use, hypogonadism): items 12306 / 12320.
• Endocrinology specialist consultation: items 132 / 133.
• ATSI Health Assessment: item 715.

PBS prescribing:

• Hydrocortisone 20 mg tablets: PBS Authority Required (Streamlined) for secondary adrenal insufficiency in the context of pituitary disease.
• Hydrocortisone sodium succinate 100 mg (Solu-Cortef) vials for emergency kit: General Schedule.
• Levothyroxine (Eutroxsig, Oroxine): General Schedule.
• Testosterone (Reandron, Testogel, others): PBS Authority Required for confirmed androgen deficiency.
• Desmopressin (Minirin nasal, oral, sublingual): PBS Authority Required (Streamlined) for central diabetes insipidus.
• Somatropin (Genotropin, Saizen, Norditropin, Omnitrope): PBS Section 100 HSD — specialist-initiated; ongoing eligibility reviewed annually.
• Plenadren (modified-release hydrocortisone): not PBS-listed; private cost approximately $300 per month.

A GPCCMP is appropriate for coordinating allied health referrals: endocrine nurse educator, exercise physiologist (bone and body composition), dietitian (cardiometabolic), pharmacist (home medication review for complex polypharmacy), and psychologist (chronic illness adjustment).

E. Special populations

Head injury survivors. Pituitary dysfunction after moderate-to-severe TBI is substantially underdiagnosed in Australian general practice. Any patient presenting with unexplained fatigue, low blood pressure, low libido, or sexual dysfunction months after a significant head injury warrants screening with paired 9 am cortisol/ACTH, fT4/TSH, and testosterone or oestradiol. (Schneider et al., JAMA 2007)

ICI cancer therapy patients. Any cancer patient on ipilimumab, nivolumab, pembrolizumab, or combination immunotherapy who develops new headache, fatigue, or low blood pressure requires an urgent pituitary hormone screen. ICI-induced hypophysitis tends to damage the ACTH and TSH axes selectively. Ongoing ICI re-challenge requires endocrinology and oncology co-ordination.

Pregnancy. Hypopituitarism in pregnancy requires specialist obstetric endocrinology input. Cortisol requirements increase in the third trimester and during labour. Sex-hormone replacement is adjusted through pregnancy. Growth hormone therapy is not recommended in pregnancy.

Older adults. Fatigue, cold intolerance, cognitive slowing, and low libido overlap with common age-related changes and can mask hypopituitarism for years. Unexplained low bone density in combination with other symptoms should prompt pituitary investigation. Driving fitness is assessed per Austroads fitness-to-drive guidelines if hypoglycaemia from cortisol deficiency or uncontrolled diabetes insipidus is a concern.

Women of reproductive age. Gonadotrophin therapy for fertility-seeking patients requires a fertility specialist. Hydroxyurea and certain pituitary medications carry teratogenicity risks; reliable contraception until fertility management is planned is essential.

When to escalate

Refer or escalate when:

• Pituitary apoplexy is suspected — sudden severe retro-orbital or thunderclap headache, double vision, visual loss, or collapse. Give IV or IM hydrocortisone 100 mg immediately and activate emergency services; this is a neurosurgical emergency requiring immediate hospital transfer.
• Any newly confirmed or suspected hypopituitarism — all confirmed cases require endocrinology review and involvement of a pituitary multidisciplinary team for axis workup and replacement initiation.
• Adrenal crisis — shock, inability to take oral cortisol due to vomiting or unconsciousness, confusional state. IM hydrocortisone and emergency department attendance.
• ICI-treated cancer patient with new pituitary symptoms — same-day oncology and endocrinology.
• Adult growth hormone deficiency with significant quality-of-life impairment — referral for confirmatory stimulation testing and PBS Section 100 qualification.
• Fertility-seeking patients — gonadotrophin therapy or GnRH pulsatile therapy requires specialist fertility services.

What this article is and is not

This is general health information about hypopituitarism, drawn from current Australian endocrinology practice guidelines — Therapeutic Guidelines (eTG), the Endocrine Society of Australia, the Australian Medicines Handbook, Pituitary Foundation Australia, and Addisons Australia. It is not personal medical advice and does not create a doctor–patient relationship.

Individual decisions about which hormonal axes to replace, at what doses, in what sequence, and with what monitoring plan are made by an endocrinologist working together with the GP and the patient.

For patient support and plain-language information: Pituitary Foundation Australia, Hormones Australia, Addisons Australia, HealthDirect — Hypopituitarism, Better Health Channel.

For acute mental health crisis: Lifeline 13 11 14, Beyond Blue 1300 22 4636.

---

Sources cited

1. Fleseriu M et al. — Endocrine Society 2016 Guideline: Hormonal Replacement in Hypopituitarism (JCEM 2016)
2. Therapeutic Guidelines (eTG) — Hypopituitarism and pituitary disease
3. Endocrine Society of Australia
4. Australian Medicines Handbook
5. Pituitary Foundation Australia
6. Hormones Australia
7. Addisons Australia
8. HealthDirect — Hypopituitarism
9. Higham CE et al. Hypopituitarism. Lancet 2016
10. Schneider HJ et al. JAMA 2007 — TBI and hypothalamic-pituitary dysfunction
11. Hahner S et al. Eur J Endocrinol 2015 — Adrenal crisis prevention
12. Pharmaceutical Benefits Scheme
13. Austroads — Assessing Fitness to Drive
14. Better Health Channel